Everything below concerns PT-141 code. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-08. Numbers and descriptions here follow the published literature rather than marketing material.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R | Highest reported agonist potency within the family |
| Secondary receptor activity | MC1R and MC3R | Lower potency than at MC4R |
| Elimination half-life | About 2 to 3 hours | Measured after subcutaneous administration |
| Plasma protein binding | Approximately 44 percent | Species- and assay-dependent |
| Route of administration | Subcutaneous injection | Reviewed product uses a single-use device |
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Darryl Kile, a former teammate with the Astros, died of a heart attack on June 22, 2002, while an active player for the Cardinals, before a game against the Cubs. The Darryl Kile Good Guy Award was established in his honor, annually for one player on both the Cardinals and the Astros. Bagwell was the first recipient for the Astros in 2003. Ken Caminiti, another former teammate of Bagwell's, died on October 10, 2004. Bagwell delivered a eulogy at his funeral. Bagwell is a recovering alcoholic. He struggled with addiction for several years until 2017.
== Research == Starting in the 1980's DeGrado's group developed the approach of de novo protein design, a term they coined to describe the design of proteins from first principles rather than through modification of natural protein sequences. They pioneered parametric approaches to the design of water-soluble 4-helix (alpha4) and 3-helix bundles (alpha3D), and ion channel peptides. The protein, alpha3D, was notable at the time, because it was the premier example of a de novo protein, which was biologically expressed, structurally validated, and whose sequence and structure were not based on the sequence or the precise tertiary structure of a natural protein. The sequence of alpha3D was designed using the computational sidechain repacking algorithms that had recently been developed by Ponders & Richards, Desjarlais & Handel, Dahiyat & Mayo. The folding kinetics of alpha3D are among the most extensively characterized of single-domain proteins, and it has been used as a template for design of metalloproteins. The company Arcellx used alpha3D as a starting point for design of chimeric antigen receptors (CARs). Clinical data announced in 2020 showed deep and durable responses of multiple myeloma, illustrating the potential of de novo proteins for treatment of human disease.
In 1987, Toni Schumacher recounted a huge amount of hormones, pills and injections (Liesen, head of the doctor team, injected 3,000 himself) being used by national players during the World Cup 1986 in Mexico (see next chapter). Argentina took "speedy coffee" before the qualifier for the 1994 World Cup against Australia, at least this is what Maradona said in May 2011. It should make them run faster, but also caused sleeping problems. He also found it suspicious that only the deciding match (against Australia) had no anti-doping control. Grondona, chairman of AFA back then, responded that there were no tests because Maradona, who already had a drug history, might not have passed. Maradona tested positive in the world cup. Immediately after the World Cup 1998, all of the drug testing samples were destroyed. If the same had happened in the Tour de France, former WADA director Alain Garnier argued that Lance Armstrong would not have been caught. Marie-George Buffet, sports minister at that time, also recalls that she felt pressurised when she initiated an unannounced test in December 1997. There were no more unannounced tests after that. Jean-Pierre Paclet, physician of Les Bleus in 1998, mentions "abnormal haematocrit values" in his book. Gary Neville, former English international, recalled that "some of the players started taking injections from ... a Frenchman called Dr Rougier". After some felt an energy boost, there was "a queue to see the doctor before the Argentina match".
=== Alleviation of dysphoria theory === The alleviation of dysphoria theory suggests that people with severe mental illness commonly have a negative self-image, which makes them vulnerable to using psychoactive substances to alleviate these feelings. Despite the existence of a wide range of dysphoric feelings (anxiety, depression, boredom, and loneliness), the literature on self-reported reasons for use seems to lend support for the experience of these feelings being the primary motivator for alcohol use disorder and other drug misuse.
Sources: en.wikipedia.org
Ribosomal DNA (rDNA) is more vulnerable to DNA damage than DNA elsewhere in the genome such that rDNA instability can lead to cellular senescence, and thus to SASP The high-mobility group proteins (HMGA) can induce senescence and SASP in a p53-dependent manner. Activation of the retrotransposon LINE1 can result in cytosolic DNA that activates the cGAS–STING cytosolic DNA sensing pathway upregulating SASP by induction of interferon type I. cGAS is essential for induction of cellular senescence by DNA damage. SASP secretion can also be initiated by the microRNAs miR-146 a/b. Senescent cells release mitochondrial double-stranded RNA (mt-dsRNA) into the cytosol driving the SASP via RIGI/MDA5/MAVS/MFN1. Moreover, senescent cells are hypersensitive to mt-dsRNA-driven inflammation due to reduced levels of PNPT1 and ADAR1.
25 April Downing Street confirms the first UK evacuation flight carrying British citizens has left Sudan. High Court documents reveal that Prince William was paid a "very large sum" by News Group Newspapers, owners of The Sun, to settle historical phone-hacking claims. Data published by the Office for National Statistics indicates government borrowing for the year up to 31 March 2023 to be £139.2bn, less than the £152bn that had been forecast by the Office for Budget Responsibility prior to the 2023 budget. 26 April Andrew Bridgen is expelled from the Conservative Party after comparing COVID-19 vaccines to the Holocaust and being found to have breached lobbying rules. The first evacuation flight from Sudan lands in the UK. The Illegal Migration Bill passes its final stage in the House of Commons, with MPs voting 289–230 in favour of the bill. The UK's Competition and Markets Authority blocks Microsoft's £55bn deal to buy US video game company Activision Blizzard, citing concerns about reduced choice for gamers and reduced innovation; the move needed the approval of competition regulators in the United States, United Kingdom and European Union. 27 April Three days of fresh train strikes are called after both ASLEF and the RMT reject a pay offer from the Rail Delivery Group. The strikes dates are announced for 13 May 31 May and 3 June (ASLEF) and 13 May (RMT).
=== 2000s === 2000: Venezuelan astrophysicist Kathy Vivas presented her discovery of approximately 100 "new and very distant" RR Lyrae stars, providing insight into the structure and history of the Milky Way galaxy. 2000: Russian gynaecologist Galina Savelyeva founded the Department of Obstetrics and Gynaecology at Moscow State University. Savelyeva was one of the first scientists in the world to demonstrate the feasibility of using craniocerebral hypothermia in the treatment of babies born with asphyxia, which formed the basis for the Russian Ministry of Health's order on the primary resuscitation of babies born with asphyxia. 2001: Danish physicist Lene Hau led a Harvard University team who used a Bose–Einstein condensate to slow down a beam of light to about 17 metres per second, then were able to stop a beam completely. 2003: Danish structural chemist and crystallographer Sine Larsen became the first female scientific research director at the European Synchrotron Radiation Facility (ESRF), where she was responsible for research in the fields of structural biology and structural chemistry. 2003: American geophysicist Claudia Alexander oversaw the final stages of Project Galileo, a space exploration mission that ended at the planet Jupiter. 2004: American biologist Linda B. Buck received the Nobel Prize in Physiology or Medicine along with Richard Axel "for their discoveries of odorant receptors and the organization of the olfactory system". 2004: American astrophysicist and radio astronomer Naomi McClure-Griffiths identified a new spiral arm of the Milky Way galaxy.
Sources: en.wikipedia.org
=== Legal status === Icatibant received orphan drug status in Australia, the EU, Switzerland, and the US for the treatment of hereditary angioedema (HAE). In the EU, the approval by the European Commission (July 2008) allows Jerini to market Firazyr in the European Union's 27 member states, as well as Switzerland, Liechtenstein and Iceland, making it the first product to be approved in all EU countries for the treatment of hereditary angioedema. In the US, the drug was granted FDA approval in August 2011.
== Influence and legacy == King Crimson have been influential both on the early 1970s progressive rock movement and numerous contemporary artists. Genesis and Yes were directly influenced by the band's usage of the mellotron, and many King Crimson band members were involved in other notable bands: Bruford in Yes; Lake in Emerson, Lake & Palmer; McDonald in Foreigner; Burrell in Bad Company, and Wetton in King Crimson spin-off U.K. and Asia. Canadian rock band Rush's drummer Neil Peart credited the adventurous and innovative style of Michael Giles as an influence on his own approach to percussion. King Crimson also influenced progressive rock keyboardist Michael Quatro, who included a cover of The Court of the Crimson King featuring guitar by Ted Nugent on his 1972 debut album Paintings. King Crimson's influence extends to many bands from diverse genres, especially of the 1990s and 2000s. Kurt Cobain, the frontman of the grunge band Nirvana, had stated that the album Red had a major influence on the sound of their final studio album In Utero. Tool are known to be heavily influenced by King Crimson, with vocalist Maynard James Keenan joking on a tour with them: "Now you know who we ripped off. Just don't tell anyone, especially the members of King Crimson." Modern progressive, experimental, psychedelic and indie rock bands have cited them as an influence as well, including MGMT, The Fierce and the Dead, the Mars Volta, Primus, Black Country, New Road, Mystery Jets, Fanfarlo, Phish, and Anekdoten, who first practiced together playing King Crimson songs.
Villa Erica (Heather Villa): suggesting a Romano-British origin Bellerīca: a medieval Latin word meaning 'dyehouse or tanhouse' Billers: a traditional name for watercress, for which Bilbrook in Somerset and Staffordshire are named. Watercress was farmed in Billericay springs during the 20th century. Although the precise etymology of the name is not known, England has places similarly named:
The capacity to store retinol in the liver means that well-nourished humans can go months on a vitamin A deficient diet without manifesting signs and symptoms of deficiency. Two liver cell types are responsible for storage and release: hepatocytes and hepatic stellate cells (HSCs). Hepatocytes take up the lipid-rich chylomicrons, bind retinol to retinol-binding protein 4 (RBP4), and transfer the retinol-RBP4 to HSCs for storage in lipid droplets as retinyl esters. Mobilization reverses the process: retinyl ester hydrolase releases free retinol which is transferred to hepatocytes, bound to RBP4, and put into blood circulation. Other than either after a meal or when consumption of large amounts exceeds liver storage capacity, more than 95% of retinol in circulation is bound to RBP4.
Sources: en.wikipedia.org
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.
Indirect evidence from animal studies supports central access, and the proposed mechanism requires it. Direct quantification in humans is limited. How much reaches specific brain regions remains an open question.
Published descriptions give a plasma half-life of roughly two to three hours after subcutaneous administration. Values vary with assay method and study population. The figure is an average rather than a fixed molecular property.
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.